Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
98%
Clinical Trial
86%
Overall Survival
84%
Malignant Neoplasm
84%
Atezolizumab
70%
Glucuronosyltransferase
65%
Randomized Controlled Trial
56%
Pharmacogenomics
47%
Progression Free Survival
45%
Congestive Heart Failure
45%
Vancomycin
45%
Uridine Diphosphate
45%
Non Small Cell Lung Cancer
45%
Neoplasm
43%
Combination Therapy
43%
Metastatic Colorectal Cancer
36%
Glycosyltransferase
36%
Monoclonal Antibody
36%
Epidermal Growth Factor Receptor
36%
Immune Checkpoint Inhibitor
36%
Chemotherapy
32%
Adverse Event
32%
Phosphotransferase Inhibitor
30%
Proton Pump Inhibitor
28%
Biological Marker
27%
Colorectal Carcinoma
27%
Medicinal Plant
22%
Pharmacogenetics
22%
Cytochrome P450
22%
Clopidogrel
21%
Irinotecan
21%
CYP2C19
21%
Lapatinib
21%
Trastuzumab Emtansine
21%
Non-Steroidal Anti-Inflammatory Drug
20%
Obesity
19%
Drug Interaction
19%
Sorafenib
18%
Afimoxifene
18%
Mortality Rate
18%
Active Metabolite
18%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
18%
Receptor
18%
microRNA
18%
Cyclophosphamide
18%
Biosimilar Agent
18%
Lung Cancer
18%
CYP3A4
18%
Multiple Myeloma
18%
Comorbidity
16%
Medicine and Dentistry
Clinical Trial
76%
Medicine
68%
Meta-Analysis
65%
Atezolizumab
57%
Breast Cancer
48%
Overall Survival
46%
Randomized Controlled Trial
44%
Neoplasm
43%
Metastatic Colorectal Cancer
36%
Congestive Heart Failure
36%
Cancer Cell
34%
Non Small Cell Lung Cancer
32%
Malignant Neoplasm
32%
Combination Therapy
29%
Pooled Analysis
29%
Progression Free Survival
28%
Patient-Reported Outcome
27%
Lung Cancer
27%
Monoclonal Antibody Therapy
27%
Immune Checkpoint Inhibitor
25%
Systematic Review
24%
Monoclonal Antibody
23%
Glucuronosyltransferase
20%
Epidermal Growth Factor Receptor
19%
Lung
18%
Personalized Medicine
18%
Proton-Pump Inhibitor
18%
Nonsteroid Antiinflammatory Agent
18%
Biosimilar
18%
Subgroup Analysis
18%
Anti-Epidermal Growth Factor Receptor
18%
Chemoimmunotherapy
18%
Pharmacogenomics
18%
Complementary Medicine
18%
Multiple Myeloma
18%
Disease
18%
Immunity
18%
Adverse Event
16%
Cancer
16%
Obesity
16%
Comorbidity
16%
Immunotherapy
15%
Clinical Study
15%
Clinician
15%
Androgen
13%
Health Care
12%
Hazard Ratio
12%
Drug Resistance
12%
Pharmacogenetic Testing
12%
Exemestane
12%
Biochemistry, Genetics and Molecular Biology
Uridine Diphosphate
100%
Glucuronosyltransferase
90%
Glycosyltransferase
85%
Metabolic Pathway
79%
Enzyme
63%
Clinical Trial
40%
Cancer Cell
34%
Overall Survival
33%
CYP3A4
31%
Glucuronidation
29%
Protein Kinase
27%
Exon
25%
Kinase
25%
Phosphotransferase
25%
UGT1A@
24%
UGT2B7
23%
Computer Simulation
23%
MicroRNA
23%
Messenger RNA
21%
Cytochrome P450
20%
Untranslated Region
19%
Immune Checkpoints
18%
Proton Pump
18%
Statin
18%
Peroxisome Proliferator-Activated Receptor
18%
Immunity
18%
Isoform
15%
Small Molecule
15%
Transcriptome
14%
Colon
13%
Binding Domain
13%
Medicinal Plant
12%
Gene Expression
12%
Circular RNA
12%
Pharmacogenetics
12%
Nuclear Receptor
12%
Androgen Receptor
12%
CYP2C9
10%
Drug Therapy
10%
UGT2B4
10%
Medline
10%
Genetic Polymorphism
10%
Atorvastatin
10%
LNCaP
10%
Aglycone
10%
Bioinformatics
10%
UGT1A8
10%
Cochrane Library
9%
Progression Free Survival
9%
Intestine Flora
9%